351 related articles for article (PubMed ID: 27089317)
1. Novel Anthranilamide-Based FXa Inhibitors: Drug Design, Synthesis and Biological Evaluation.
Wang W; Yuan J; Fu X; Meng F; Zhang S; Xu W; Xu Y; Huang C
Molecules; 2016 Apr; 21(4):491. PubMed ID: 27089317
[TBL] [Abstract][Full Text] [Related]
2. Synthesis and evaluation of anthranilamide-based derivatives as FXa inhibitors.
Huang C; Wang W; Li Y; Zhang S; Meng F; Xu W; Yuan J; Chen L
Oncotarget; 2017 Jun; 8(23):37186-37199. PubMed ID: 28415603
[TBL] [Abstract][Full Text] [Related]
3. Identification of anthranilamide derivatives as potential factor Xa inhibitors: drug design, synthesis and biological evaluation.
Xing J; Yang L; Li H; Li Q; Zhao L; Wang X; Zhang Y; Zhou M; Zhou J; Zhang H
Eur J Med Chem; 2015 May; 95():388-99. PubMed ID: 25839438
[TBL] [Abstract][Full Text] [Related]
4. Design, synthesis and biological evaluation of anthranilamide derivatives as potential factor Xa (fXa) inhibitors.
Xing J; Yang L; Zhou J; Zhang H
Bioorg Med Chem; 2018 Dec; 26(23-24):5987-5999. PubMed ID: 30446438
[TBL] [Abstract][Full Text] [Related]
5. Design, synthesis, and biological activity of novel tetrahydropyrazolopyridone derivatives as FXa inhibitors with potent anticoagulant activity.
Sun X; Hong Z; Liu M; Guo S; Yang D; Wang Y; Lan T; Gao L; Qi H; Gong P; Liu Y
Bioorg Med Chem; 2017 May; 25(10):2800-2810. PubMed ID: 28389110
[TBL] [Abstract][Full Text] [Related]
6. Design, synthesis and biological evaluation of novel 2,3-dihydroquinazolin- 4(1H)-one derivatives as potential fXa inhibitors.
Xing J; Yang L; Yang Y; Zhao L; Wei Q; Zhang J; Zhou J; Zhang H
Eur J Med Chem; 2017 Jan; 125():411-422. PubMed ID: 27689724
[TBL] [Abstract][Full Text] [Related]
7. Innovative Three-Step Microwave-Promoted Synthesis of
Santana-Romo F; Lagos CF; Duarte Y; Castillo F; Moglie Y; Maestro MA; Charbe N; Zacconi FC
Molecules; 2020 Jan; 25(3):. PubMed ID: 31979319
[TBL] [Abstract][Full Text] [Related]
8. Synthesis of 3,4-diaminobenzoyl derivatives as factor Xa inhibitors.
Yang J; Su G; Ren Y; Chen Y
Eur J Med Chem; 2015 Aug; 101():41-51. PubMed ID: 26114810
[TBL] [Abstract][Full Text] [Related]
9. Design, synthesis and structure-activity relationship of oxazolidinone derivatives containing novel S4 ligand as FXa inhibitors.
Zhao Y; Jiang M; Zhou S; Wu S; Zhang X; Ma L; Zhang K; Gong P
Eur J Med Chem; 2015; 96():369-80. PubMed ID: 25911624
[TBL] [Abstract][Full Text] [Related]
10. Structure-based design of potent, amidine-derived inhibitors of factor Xa: evaluation of selectivity, anticoagulant activity, and antithrombotic activity.
Wiley MR; Weir LC; Briggs S; Bryan NA; Buben J; Campbell C; Chirgadze NY; Conrad RC; Craft TJ; Ficorilli JV; Franciskovich JB; Froelich LL; Gifford-Moore DS; Goodson T; Herron DK; Klimkowski VJ; Kurz KD; Kyle JA; Masters JJ; Ratz AM; Milot G; Shuman RT; Smith T; Smith GF; Tebbe AL; Tinsley JM
J Med Chem; 2000 Mar; 43(5):883-99. PubMed ID: 10715155
[TBL] [Abstract][Full Text] [Related]
11. Advances in the Development of Novel Factor Xa Inhibitors: A Patent Review.
Khadse AN; Sharma MK; Murumkar PR; Rajput SJ; Yadav MR
Mini Rev Med Chem; 2018; 18(16):1332-1353. PubMed ID: 29692238
[TBL] [Abstract][Full Text] [Related]
12. Synthesis and biological evaluation of Isosteviol derivatives as FXa inhibitors.
Shi Y; Pan BW; Li WC; Wang Q; Wu Q; Pan M; Fu HZ
Bioorg Med Chem Lett; 2020 Jan; 30(2):126585. PubMed ID: 31859158
[TBL] [Abstract][Full Text] [Related]
13. Design, synthesis, and structure-activity and structure-pharmacokinetic relationship studies of novel [6,6,5] tricyclic fused oxazolidinones leading to the discovery of a potent, selective, and orally bioavailable FXa inhibitor.
Xue T; Ding S; Guo B; Zhou Y; Sun P; Wang H; Chu W; Gong G; Wang Y; Chen X; Yang Y
J Med Chem; 2014 Sep; 57(18):7770-91. PubMed ID: 25179681
[TBL] [Abstract][Full Text] [Related]
14. Synthesis and Thrombin, Factor Xa and U46619 Inhibitory Effects of Non-Amidino and Amidino N²-Thiophenecarbonyl- and N²-Tosylanthranilamides.
Lee SH; Lee W; Nguyen T; Um IS; Bae JS; Ma E
Int J Mol Sci; 2017 May; 18(6):. PubMed ID: 28561744
[TBL] [Abstract][Full Text] [Related]
15. Novel FXa Inhibitor Identification through Integration of Ligand- and Structure-Based Approaches.
Lagos CF; Segovia GF; Nuñez-Navarro N; Faúndez MA; Zacconi FC
Molecules; 2017 Sep; 22(10):. PubMed ID: 28937618
[TBL] [Abstract][Full Text] [Related]
16. Characterization of a novel selective factor Xa inhibitor, DJT06001, which reduces thrombus formation with low risk of bleeding.
Hu X; Xiao Y; Yu C; Zuo Y; Yang W; Wang X; Gu B; Li J
Eur J Pharmacol; 2018 Apr; 825():85-91. PubMed ID: 29475063
[TBL] [Abstract][Full Text] [Related]
17. Rivaroxaban and apixaban induce clotting factor Xa fibrinolytic activity.
Carter RLR; Talbot K; Hur WS; Meixner SC; Van Der Gugten JG; Holmes DT; Côté HCF; Kastrup CJ; Smith TW; Lee AYY; Pryzdial ELG
J Thromb Haemost; 2018 Nov; 16(11):2276-2288. PubMed ID: 30176116
[TBL] [Abstract][Full Text] [Related]
18. Profiling the structural determinants for the selectivity of representative factor-Xa and thrombin inhibitors using combined ligand-based and structure-based approaches.
Bhunia SS; Roy KK; Saxena AK
J Chem Inf Model; 2011 Aug; 51(8):1966-85. PubMed ID: 21761917
[TBL] [Abstract][Full Text] [Related]
19. Qualitative and quantitative pharmacophore-similarity assessment of anthranilamide-based factor Xa inhibitors: applications on similar molecules with identical biological endpoints.
Kumar SP; Rawal RM; Pandya HA; Jasrai YT
J Recept Signal Transduct Res; 2016; 36(2):189-206. PubMed ID: 26416308
[TBL] [Abstract][Full Text] [Related]
20. Design, synthesis, and structure-activity relationship of novel and effective apixaban derivatives as FXa inhibitors containing 1,2,4-triazole/pyrrole derivatives as P2 binding element.
Wang Y; Sun X; Yang D; Guo Z; Fan X; Nie M; Zhang F; Liu Y; Li Y; Wang Y; Gong P; Liu Y
Bioorg Med Chem; 2016 Nov; 24(21):5646-5661. PubMed ID: 27663548
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
